BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11:609-28. [PMID: 22827246 DOI: 10.1586/erv.12.28] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 2015;33:1235-42. [PMID: 25600519 DOI: 10.1016/j.vaccine.2015.01.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
2 Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLoS Pathog 2016;12:e1005483. [PMID: 27032093 DOI: 10.1371/journal.ppat.1005483] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
3 Wicker S, Maltezou HC. Vaccine-preventable diseases in Europe: where do we stand? Expert Review of Vaccines 2014;13:979-87. [DOI: 10.1586/14760584.2014.933077] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
4 Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine 2018;36:6979-87. [PMID: 30314910 DOI: 10.1016/j.vaccine.2018.09.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pérez-Martínez AS, Acevedo-Padilla SA, Bibbins-Martínez M, Galván-Alonso J, Rosales-Mendoza S. A perspective on the use of Pleurotus for the development of convenient fungi-made oral subunit vaccines. Vaccine 2015;33:25-33. [PMID: 25444808 DOI: 10.1016/j.vaccine.2014.10.059] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Collier MA, Junkins RD, Gallovic MD, Johnson BM, Johnson MM, Macintyre AN, Sempowski GD, Bachelder EM, Ting JP, Ainslie KM. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Mol Pharm 2018;15:4933-46. [PMID: 30281314 DOI: 10.1021/acs.molpharmaceut.8b00579] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
7 Thakur KT, Epstein S, Bilski A, Balbi A, Boehme AK, Brannagan TH, Wesley SF, Riley CS. Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present. Neurology 2021;97:767-75. [PMID: 34475124 DOI: 10.1212/WNL.0000000000012703] [Reference Citation Analysis]
8 Smith AJ, Li Y, Bazin HG, St-Jean JR, Larocque D, Evans JT, Baldridge JR. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. Vaccine 2016;34:4304-12. [PMID: 27402566 DOI: 10.1016/j.vaccine.2016.06.080] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
9 Li Z, Cui K, Wang H, Liu F, Huang K, Duan Z, Wang F, Shi D, Liu Q. A milk-based self-assemble rotavirus VP6-ferritin nanoparticle vaccine elicited protection against the viral infection. J Nanobiotechnology 2019;17:13. [PMID: 30670042 DOI: 10.1186/s12951-019-0446-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
10 Pellett PE, Mitra S, Holland TC. Basics of virology. Handb Clin Neurol 2014;123:45-66. [PMID: 25015480 DOI: 10.1016/B978-0-444-53488-0.00002-X] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
11 Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014;21:31. [PMID: 24742252 DOI: 10.1186/1423-0127-21-31] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
12 Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 2021;6:28. [PMID: 33619260 DOI: 10.1038/s41541-021-00292-w] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 66.0] [Reference Citation Analysis]
13 Kumar P, Sunita, Dubey KK, Shukla P. Whole-Cell Vaccine Preparation: Options and Perspectives. Methods Mol Biol 2021;2183:249-66. [PMID: 32959248 DOI: 10.1007/978-1-0716-0795-4_13] [Reference Citation Analysis]
14 Nikolaidis M, Mimouli K, Kyriakopoulou Z, Tsimpidis M, Tsakogiannis D, Markoulatos P, Amoutzias GD. Large-scale genomic analysis reveals recurrent patterns of intertypic recombination in human enteroviruses. Virology 2019;526:72-80. [DOI: 10.1016/j.virol.2018.10.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
15 Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LFP. Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease. Front Microbiol 2017;8:2249. [PMID: 29238324 DOI: 10.3389/fmicb.2017.02249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
16 Linero F, Sepúlveda C, Christopoulou I, Hulpiau P, Scolaro L, Saelens X. Neutralization of Junín virus by single domain antibodies targeted against the nucleoprotein. Sci Rep 2018;8:11451. [PMID: 30061671 DOI: 10.1038/s41598-018-29508-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Sartori AM, Vicentine MP, Gryninger LC, Soárez PC, Novaes HM. Polio inactivated vaccine costs into routine childhood immunization in Brazil. Rev Saude Publica 2015;49:8. [PMID: 25741645 DOI: 10.1590/s0034-8910.2015049005492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kyriakopoulou Z, Pliaka V, Amoutzias GD, Markoulatos P. Recombination among human non-polio enteroviruses: implications for epidemiology and evolution. Virus Genes 2015;50:177-88. [PMID: 25537948 DOI: 10.1007/s11262-014-1152-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
19 Resch TK, Wang Y, Moon S, Jiang B. Serial Passaging of the Human Rotavirus CDC-9 Strain in Cell Culture Leads to Attenuation: Characterization from In Vitro and In Vivo Studies. J Virol 2020;94:e00889-20. [PMID: 32461318 DOI: 10.1128/JVI.00889-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Policicchio BB, Pandrea I, Apetrei C. Population Bottlenecks and Pathogen Extinction: "Make This Everyone's Mission to Mars, Including Yours". J Virol 2015;89:8104-6. [PMID: 26018162 DOI: 10.1128/JVI.00920-15] [Reference Citation Analysis]
21 Rouxel RN, Mérour E, Biacchesi S, Brémont M. Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines. PLoS One 2016;11:e0164245. [PMID: 27711176 DOI: 10.1371/journal.pone.0164245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Hsieh MS, Hsu CW, Tu LL, Chai KM, Yu LL, Wu CC, Chen MY, Chiang CY, Liu SJ, Liao CL, Chen HW. Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses. Front Immunol 2021;12:751883. [PMID: 34707615 DOI: 10.3389/fimmu.2021.751883] [Reference Citation Analysis]
23 Zhang M, Zhang Y, Hong M, Xiao J, Han Z, Song Y, Zhu S, Yan D, Yang Q, Xu W, Liu Z. Molecular typing and characterization of a novel genotype of EV-B93 isolated from Tibet, China. PLoS One 2020;15:e0237652. [PMID: 32841272 DOI: 10.1371/journal.pone.0237652] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Peres C, Matos AI, Conniot J, Sainz V, Zupančič E, Silva JM, Graça L, Sá Gaspar R, Préat V, Florindo HF. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater 2017;48:41-57. [PMID: 27826003 DOI: 10.1016/j.actbio.2016.11.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
25 Karch CP, Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol 2016;120:1-14. [PMID: 27157411 DOI: 10.1016/j.bcp.2016.05.001] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 21.0] [Reference Citation Analysis]
26 Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine 2015;33:6611-6. [PMID: 26529068 DOI: 10.1016/j.vaccine.2015.10.091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014;111:12283-12287. [PMID: 25136134 DOI: 10.1073/pnas.1400472111] [Cited by in Crossref: 193] [Cited by in F6Publishing: 164] [Article Influence: 27.6] [Reference Citation Analysis]
28 Vet LJ, Setoh YX, Amarilla AA, Habarugira G, Suen WW, Newton ND, Harrison JJ, Hobson-Peters J, Hall RA, Bielefeldt-Ohmann H. Protective Efficacy of a Chimeric Insect-Specific Flavivirus Vaccine against West Nile Virus. Vaccines (Basel) 2020;8:E258. [PMID: 32485930 DOI: 10.3390/vaccines8020258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
29 Sprygin A, Babin Y, Pestova Y, Kononova S, Wallace DB, Van Schalkwyk A, Byadovskaya O, Diev V, Lozovoy D, Kononov A. Analysis and insights into recombination signals in lumpy skin disease virus recovered in the field. PLoS One 2018;13:e0207480. [PMID: 30540759 DOI: 10.1371/journal.pone.0207480] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
30 Gao J, Kang G, Hu R, Zhang L, Yu J, Wang Z, Tang F. Adverse events following immunization with bivalent oral poliovirus vaccine in Jiangsu, China. Br J Clin Pharmacol 2021. [PMID: 34240463 DOI: 10.1111/bcp.14976] [Reference Citation Analysis]
31 Kim GL, Seon SH, Rhee DK. Pneumonia and Streptococcus pneumoniae vaccine. Arch Pharm Res 2017;40:885-93. [PMID: 28735461 DOI: 10.1007/s12272-017-0933-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
32 Yong CY, Ong HK, Tang HC, Yeap SK, Omar AR, Ho KL, Tan WS. Infectious hematopoietic necrosis virus: advances in diagnosis and vaccine development. PeerJ 2019;7:e7151. [PMID: 31341728 DOI: 10.7717/peerj.7151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
33 Dimier-poisson I, Carpentier R, N'guyen TTL, Dahmani F, Ducournau C, Betbeder D. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials 2015;50:164-75. [DOI: 10.1016/j.biomaterials.2015.01.056] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
34 Nasir SG, Aliyu G, Ya'u I, Gadanya M, Mohammad M, Zubair M, El-Kamary SS. From intense rejection to advocacy: how Muslim clerics were engaged in a polio eradication initiative in Northern Nigeria. PLoS Med 2014;11:e1001687. [PMID: 25093661 DOI: 10.1371/journal.pmed.1001687] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
35 Sanders BP, Liu Y, Brandjes A, van Hoek V, de Los Rios Oakes I, Lewis J, Wimmer E, Custers JHHV, Schuitemaker H, Cello J, Edo-Matas D. Brunenders: a partially attenuated historic poliovirus type I vaccine strain. J Gen Virol 2015;96:2614-22. [PMID: 26018960 DOI: 10.1099/vir.0.000197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Hernández-Adame L, Angulo C, García-Silva I, Palestino G, Rosales-Mendoza S. An overview of nanogel-based vaccines. Expert Rev Vaccines 2019;18:951-68. [PMID: 31487213 DOI: 10.1080/14760584.2019.1647783] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]